Medically reviewed by Jay N. Yepuri, MD Primary sclerosing cholangitis (PSC) is a progressive scarring of the liver's bile ducts. According to current estimates, between 5 and 16 in every 100,000 ...

Given the uncertainty surrounding the pathogenesis of the disease, a number of different medical therapies have been studied in the treatment of PSC. However, there currently are no effective ...

Objectives Primary sclerosing cholangitis (PSC) is a rare chronic disease that presents challenges to both patients and ...

However, there is still no evidence supporting a specific medical therapy capable of halting disease progression in PSC, and none of the drugs discussed below has been approved for the treatment ...

For this reason, care for PSC is best in major academic medical centers, such as Baylor St. Luke’s Medical Center, which offers liver transplantation. Close communication between the specialty ...

In a recent study published in the Journal of Crohn’s and Colitis, researchers showed that oral vancomycin (OV) induces clinical remission in primary sclerosing cholangitis-associated inflammatory ...

However, a recent randomized, controlled trial has surprisingly shown that the use of high-dose UDCA in patients with primary sclerosing cholangitis (PSC) may be harmful; adverse events ...

The Public Administration Reform Commission has proposed renaming the BCS (Health) cadre as the Bangladesh Health Service, ...

An antibiotic used to treat infective diarrhoea could be an effective drug for a type of inflammatory bowel disease, a new study has found.